Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Breast Cancer

NCT01367028 is registered in ClinicalTrials.gov with Austrian Breast & Colorectal Cancer Study Group as lead sponsor.

NCT NCT01367028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01367028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Breast Cancer
Lead sponsor
Austrian Breast & Colorectal Cancer Study Group
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
April 30, 2014
Enrollment
100 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer